Centessa Pharmaceuticals Announces Dosing Of First Subject In Registrational PRESent-2 Study Evaluating SerpinPC For Treatment Of Hemophilia B without Inhibitors
Portfolio Pulse from Benzinga Newsdesk
Centessa Pharmaceuticals has announced the dosing of the first subject in its registrational PRESent-2 study, which is evaluating SerpinPC for the treatment of Hemophilia B without inhibitors.
July 10, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Centessa Pharmaceuticals' initiation of dosing in the PRESent-2 study could potentially lead to a new treatment for Hemophilia B, which may positively impact the company's stock in the short term.
The initiation of dosing in a new study is a significant step in the development of a new drug. If the study yields positive results, it could lead to the approval of a new treatment for Hemophilia B, which would likely increase the value of Centessa Pharmaceuticals' stock.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100